Our Pricing

Switching From Mounjaro To Wegovy: Clinical Guidance & UK Wait Times

Switching from Mounjaro to Wegovy is a common transition for UK patients seeking weight loss treatment, often driven by price differences, supply availability, or clinical response. As a UK-registered pharmacy with over a decade of experience supporting weight management patients, we've guided thousands through this exact medication change. This page provides evidence-based guidance on wait times, dose conversion, efficacy differences, and what to expect when transitioning from tirzepatide to semaglutide under UK prescriber supervision.

Why Patients Consider Switching From Mounjaro To Wegovy

Many UK patients explore switching from Mounjaro to Wegovy due to significant price differences — Wegovy starts from £124.99 compared to Mounjaro at £124.99, representing potential annual savings exceeding £124.99 for ongoing treatment [1]. Supply chain stability also influences decisions, as Wegovy availability has improved considerably across UK pharmacies since late 2023, while Mounjaro stock can fluctuate regionally.

Clinical response plays an equally important role in medication transitions. While tirzepatide (Mounjaro) demonstrated superior average weight loss in head-to-head trials — with SURPASS-2 showing 12.4% body weight reduction at 40 weeks versus 6.7% for semaglutide — individual patient responses vary significantly [2]. Some patients experience better tolerability or more consistent appetite suppression with semaglutide, making Wegovy a clinically appropriate alternative despite slightly lower average efficacy in population studies.

Insurance coverage and NHS prescription pathways increasingly favour semaglutide formulations due to established NICE guidance and longer UK market presence. Patients initially self-funding Mounjaro may find Wegovy more accessible through future NHS routes, though all GLP-1 receptor agonists currently require private prescription for weight management in most UK regions outside specialist obesity services.

Cost Comparison When Switching From Mounjaro To Wegovy

At Cured Pharmacy, Wegovy treatment starts from £124.99 per month compared to Mounjaro at £124.99, with both prices including UK prescriber consultation and next-day delivery across England, Scotland, and Wales. First-time patients receive £20 off using code Weightlossnew, reducing initial Wegovy cost to £124.99. These transparent upfront prices apply before clinical assessment, allowing patients to plan treatment costs accurately when considering medication switches.

Long-term treatment economics matter significantly for chronic weight management. Over a typical 12-month maintenance period, switching from Mounjaro to Wegovy could reduce annual medication expenditure by approximately £124.99 assuming consistent monthly dosing at maintenance levels. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) regularly advises patients that cost sustainability directly impacts treatment adherence — the most effective weight loss medication is the one patients can afford to continue long-term.

Wait Times When Switching From Mounjaro To Wegovy

The recommended wait time when switching from Mounjaro to Wegovy depends on your current tirzepatide dose and treatment duration. For patients on stable Mounjaro maintenance doses (10mg or 12.5mg weekly), most UK prescribers advise starting Wegovy within 7 days of the last Mounjaro injection to maintain consistent GLP-1 receptor activation and appetite control [3]. This overlap window prevents the rebound hunger that can occur when GLP-1 levels drop significantly between medications.

Patients experiencing side effects on Mounjaro may benefit from a longer washout period before switching from Mounjaro to Wegovy. If you've had persistent nausea, vomiting, or gastrointestinal symptoms on tirzepatide, allowing 10-14 days clearance can help distinguish which medication causes your specific tolerability issues, since both drugs share similar side effect profiles but individual responses vary considerably.

Clinical assessment timing matters for prescription continuity. At Cured Pharmacy, our UK-registered prescribers can complete your Wegovy consultation within 24 hours, but stock allocation and delivery logistics mean you should initiate your switch request at least 5-7 days before your final Mounjaro dose runs out. This buffer prevents treatment gaps that could compromise weight loss momentum and metabolic benefits achieved during your Mounjaro course.

Dose Conversion When Switching From Mounjaro To Wegovy

Dose equivalence between Mounjaro and Wegovy isn't straightforward because tirzepatide acts on both GLP-1 and GIP receptors, while semaglutide targets GLP-1 only. Most UK prescribers restart Wegovy at the standard 0.25mg weekly titration schedule regardless of your final Mounjaro dose, as this approach minimises gastrointestinal side effects and allows proper tolerance assessment for the new medication [4]. Patients switching from Mounjaro to Wegovy should not expect to transfer directly to an equivalent maintenance dose.

The Wegovy titration schedule progresses from 0.25mg weekly for 4 weeks, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg maintenance — each step lasting 4 weeks. This 20-week escalation may feel frustratingly slow for patients previously stable on Mounjaro 10mg or 12.5mg, but clinical trial data consistently shows that rapid semaglutide dose increases significantly raise discontinuation rates due to nausea and vomiting. Our prescribers occasionally approve accelerated titration (2-week intervals) for highly tolerant patients with prior GLP-1 experience, though this remains off-licence and requires careful monitoring.

Weight loss may plateau temporarily during the early Wegovy titration weeks after switching from Mounjaro to Wegovy, particularly if you were on higher tirzepatide doses. SURPASS-2 trial data showed tirzepatide 15mg produced 12.4% weight reduction versus 6.7% for semaglutide 1mg at 40 weeks, though real-world UK patient outcomes show considerable individual variation [2]. Maintaining dietary habits and physical activity established during Mounjaro treatment helps preserve weight loss momentum during the transition period.

Clinical Considerations For Switching From Mounjaro To Wegovy

Gastrointestinal tolerability often differs between tirzepatide and semaglutide despite their mechanistic similarities. Approximately 30-40% of patients in STEP trials reported nausea with semaglutide, compared to 20-25% in SURPASS trials with tirzepatide, though direct comparison is complicated by different trial populations and dose escalation schedules [1][4]. Patients who tolerated Mounjaro well may still experience nausea when switching to Wegovy, particularly if titration is rushed.

Blood glucose effects require monitoring for patients with type 2 diabetes switching from Mounjaro to Wegovy. Tirzepatide's dual GIP/GLP-1 action produces slightly greater HbA1c reductions than semaglutide alone — SURPASS-2 showed 2.01% HbA1c decrease with tirzepatide 15mg versus 1.86% with semaglutide 1mg [2]. Diabetic patients should increase home glucose monitoring frequency during the first 4-6 weeks after switching and report any hypoglycaemia episodes to their prescriber immediately, as insulin or sulfonylurea doses may require adjustment.

Efficacy Expectations After Switching From Mounjaro To Wegovy

Average weight loss outcomes differ between tirzepatide and semaglutide in clinical trials, though individual responses vary considerably. The STEP 1 trial demonstrated 14.9% average body weight reduction with semaglutide 2.4mg at 68 weeks, while SURMOUNT-1 showed 20.9% reduction with tirzepatide 15mg at 72 weeks [1][4]. These population averages don't predict individual outcomes — some patients achieve better results with Wegovy than they did with Mounjaro due to personal metabolic factors and medication tolerability.

Appetite suppression patterns may change when switching from Mounjaro to Wegovy, as the dual GIP/GLP-1 mechanism produces different satiety signalling than GLP-1 activation alone. Most patients report that hunger control remains effective after transitioning to semaglutide, though the subjective quality of appetite reduction can feel different — some describe Wegovy as producing more consistent baseline appetite suppression, while Mounjaro created stronger post-meal satiety. These experiential differences don't correlate reliably with weight loss outcomes in our clinical experience.

Maintenance phase weight stability after switching from Mounjaro to Wegovy depends heavily on lifestyle factor consistency. The STEP trial extension data showed that patients maintaining semaglutide 2.4mg for 104 weeks sustained average weight loss without significant regain, provided treatment continued [4]. Patients who established strong dietary and activity habits during Mounjaro treatment generally preserve their weight loss through the Wegovy transition, while those relying primarily on medication effects may experience temporary plateaus during dose titration.

How To Switch From Mounjaro To Wegovy Through Cured Pharmacy

Starting your transition from Mounjaro to Wegovy requires a new clinical assessment with our UK-registered prescribers, even if you have an active Mounjaro prescription elsewhere. Complete our 3-minute online consultation at https://curedpharmacy.com/pages/medical-consultancy, providing your current tirzepatide dose, treatment duration, weight loss achieved, and any side effects experienced. Our prescribers review your medical history within 24 hours and determine appropriate Wegovy starting dose and titration schedule based on your individual Mounjaro response.

Prescription approval triggers immediate stock allocation from our UK-licensed wholesalers, with next-day delivery across England, Scotland, and Wales via tracked courier in 100% discreet packaging. Your first Wegovy shipment includes comprehensive injection technique guidance and titration schedule documentation, plus direct access to our pharmacist support line for any questions during your medication transition. We coordinate delivery timing with your remaining Mounjaro supply to prevent treatment gaps that could compromise weight loss continuity.

Ongoing clinical monitoring continues throughout your Wegovy treatment at Cured Pharmacy. Our prescribers require check-in consultations every 12 weeks to assess weight loss progress, tolerability, and dose optimisation needs when switching from Mounjaro to Wegovy. These follow-up assessments ensure your semaglutide treatment remains clinically appropriate and effective, with dose adjustments made based on your individual response rather than rigid protocol adherence. All prescription renewals include the same rigorous clinical review as your initial assessment.

Switching From Mounjaro To Wegovy: Prescription Requirements

Both Mounjaro and Wegovy are prescription-only medicines in the UK, requiring clinical assessment by a GMC-registered prescriber before supply. Your existing Mounjaro prescription does not automatically transfer to Wegovy — semaglutide requires separate prescribing authorisation based on current clinical status, BMI, weight loss history, and contraindication screening. Our online consultation captures all necessary medical information for safe prescribing, including cardiovascular history, diabetic status, thyroid conditions, and concurrent medications that may interact with GLP-1 receptor agonists.

MHRA regulations require that all weight management prescriptions demonstrate clinical appropriateness through documented BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities) and previous weight loss attempts. Patients switching from Mounjaro to Wegovy typically meet these criteria through their existing treatment history, though our prescribers verify current weight and reassess suitability at each prescription issue. This regulatory framework protects patient safety while ensuring appropriate access to effective obesity pharmacotherapy.

Side Effects When Switching From Mounjaro To Wegovy

Gastrointestinal side effects remain the most common concern when switching from Mounjaro to Wegovy, affecting 30-50% of patients during dose escalation. Nausea, diarrhoea, constipation, and abdominal discomfort occur with both medications due to shared GLP-1 receptor mechanisms that slow gastric emptying [3]. Patients who experienced minimal side effects on tirzepatide may still develop symptoms with semaglutide, particularly if titration proceeds too rapidly or if dietary habits change during the medication switch.

Practical management strategies reduce side effect burden during the Mounjaro to Wegovy transition. Eating smaller, more frequent meals rather than large portions helps accommodate slower gastric emptying. Avoiding high-fat foods, staying well-hydrated, and timing injections in the evening (so peak nausea occurs during sleep) improve tolerability for most patients. Our pharmacist team recommends keeping ginger tea, plain crackers, and anti-nausea medication (cyclizine or prochlorperazine, available on separate prescription) readily available during the first 8 weeks of Wegovy titration.

Serious side effects require immediate medical attention and may necessitate treatment discontinuation. Contact your GP or NHS 111 immediately if you develop severe abdominal pain (possible pancreatitis), persistent vomiting preventing fluid intake (dehydration risk), visual changes, or signs of thyroid swelling. While these complications remain rare — pancreatitis occurred in <0.2% of STEP trial participants — patients switching from Mounjaro to Wegovy should understand warning signs and reporting procedures [4]. Our prescribers provide detailed safety information with every Wegovy prescription, including 24/7 access to pharmacist advice for urgent concerns.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 64-77. [accessed 15 August 2026]
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.